Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Clark on the Potential of Immunotherapy in Renal Cell Carcinoma

Peter Clark, MD
Published: Thursday, Oct 25, 2018



Peter Clark, MD, medical oncologist, Levine Cancer Institute, discusses the potential of immunotherapy in the treatment of patients with renal cell carcinoma (RCC).

Checkpoint inhibition holds a lot of promise in the treatment landscape of RCC, says Clark. That class of therapy, notes Clark, ramps up a patient’s immune system and releases the brakes that were put in place to inhibit the immune system’s ability to fight the cancer. Though it is not effective for every patient with RCC, it has shown tremendous activity in those in which it works.

Checkpoint inhibition has also made a big impact on the treatment landscape of advanced bladder cancer, says Clark. Ongoing trials are looking at the optimal space in which to place these therapies. Clinical trials are looking at patients with metastatic disease, locally advanced disease, and even earlier-stage disease. Immunotherapy has likely been the biggest development in bladder cancer, concludes Clark.


Peter Clark, MD, medical oncologist, Levine Cancer Institute, discusses the potential of immunotherapy in the treatment of patients with renal cell carcinoma (RCC).

Checkpoint inhibition holds a lot of promise in the treatment landscape of RCC, says Clark. That class of therapy, notes Clark, ramps up a patient’s immune system and releases the brakes that were put in place to inhibit the immune system’s ability to fight the cancer. Though it is not effective for every patient with RCC, it has shown tremendous activity in those in which it works.

Checkpoint inhibition has also made a big impact on the treatment landscape of advanced bladder cancer, says Clark. Ongoing trials are looking at the optimal space in which to place these therapies. Clinical trials are looking at patients with metastatic disease, locally advanced disease, and even earlier-stage disease. Immunotherapy has likely been the biggest development in bladder cancer, concludes Clark.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x